Get Social With Us

State of the biosimilar industry and implications for technology

Presented at:

DCAT Week 2014; 2014 Mar 10-13; New York, NY

The impending patent cliff for many high-value innovator biopharmaceutical products offers significant opportunities for the biosimilar industry, whose market is estimated to grow from $243 million in 2010 to $3.7 billion by 2015 in the United States, Europe, and Japan. One primary success factor for individual companies will be access to biopharmaceutical development and manufacturing capabilities and capacity. This presentation explores the implications of technology, partnerships, and global regulatory landscape on overall manufacturing capacity and evaluates strategic options for individual biosimilar companies.